Insulin degludec lowers risk of recurrent low blood sugar or has similar risk to insulin glargine

June 18, 2013

Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia— low blood sugar— compared with the commercially available insulin glargine, a new meta-analysis study finds. Results of the combined analysis, of five completed clinical trials, will be presented Tuesday at The Endocrine Society's 95th Annual Meeting in San Francisco.

The studies included nearly 3,400 adults with type 2 diabetes who had a daily injection of either insulin degludec or glargine combined with either a mealtime insulin or oral diabetic medications.

"Compared with , insulin degludec may offer considerable benefits by reducing the major side effect of , hypoglycemia," said the study's principal investigator, Alan Garber, MD, PhD, professor of medicine, biochemistry and molecular biology, and at Baylor College of Medicine, Houston.

Insulin degludec is not yet approved by the U.S. but is commercially available in some other countries. Because it has a longer duration of action than insulin glargine, Garber said it was important to determine whether this affects the likelihood of patients having recurrent episodes of hypoglycemia. The study authors defined recurrent hypoglycemia as a confirmed , or , level less than 56 milligrams per deciliter (or a level so severe that the patient required assistance) within 24 hours of another such episode.

Of the patients in the five studies, 2,262 took insulin degludec and 1,110 used insulin glargine, the authors reported. Four trials compared these two basal, or long-acting, insulins in combination with oral diabetic medications (insulin-oral therapy). One study, analyzed separately from the others, compared the insulins combined with a bolus, or fast-acting mealtime, insulin, called aspart (insulin-only therapy).

Denmark-headquartered Novo Nordisk, the manufacturer of insulin degludec, funded the meta-analysis and provided statistical analysis.

Results showed that 38 percent of patients taking insulin degludec and 43 percent of patients using insulin glargine experienced recurrent hypoglycemia in the insulin-only trial, compared with 6.1 and 6.6 percent with degludec and glargine, respectively, in the insulin-oral therapy trials. For all five trials, there was no significant difference in the rates of recurrent hypoglycemia, according to the abstract. For the insulin-only trial, there was reportedly a 27 percent lower rate of recurrent hypoglycemia for patients taking insulin degludec versus insulin glargine.

"This study shows that insulin degludec is an appropriate therapy for use in different treatment regimens for patients with type 2 diabetes," Garber said.

Nearly one-third of patients with type 2 diabetes use insulin therapy, he stated. -induced hypoglycemia is one of the most common reasons for emergency room visits by older adults, Garber said, citing a November 2011 study published in The New England Journal of Medicine.

"Decreasing the risk of hypoglycemia in diabetic patients is a benefit to both the patient and the insurer," he said.

Explore further: Experimental insulin drug prevents low blood sugar

Related Stories

Experimental insulin drug prevents low blood sugar

June 25, 2012

An experimental insulin drug prevented low blood sugar among diabetic patients more often than a popular drug on the market, a new study finds. The results will be presented at The Endocrine Society's 94th Annual Meeting ...

Insulin glargine's main metabolic effect as metabolite M1

October 25, 2012

(HealthDay)—For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration ...

Alternative fuel for your brain

April 1, 2013

Tight control of blood glucose levels is critical to mitigating the long-term complications of diabetes; however, the intensive insulin therapy required for this control is frequently accompanied by recurrent episodes of ...

Insulin resistance linked to weaker bones

June 17, 2013

Reduced effectiveness of the hormone insulin, or insulin resistance, is associated with weakened bones, a clinical study shows. The results were presented Sunday at The Endocrine Society's 95th Annual Meeting in San Francisco.

Recommended for you

Major fall in diabetes-related amputations since the 1990s

November 22, 2015

A major new study has found a significant reduction in diabetes-related amputations since the mid-1990s, credited to improvements in diabetes care over this period. The research is published in Diabetologia (the journal of ...

Blocking immune cell treats new type of age-related diabetes

November 18, 2015

Diabetes is often the result of obesity and poor diet choices, but for some older adults the disease might simply be a consequence of aging. New research has discovered that diabetes—or insulin resistance—in aged, lean ...

Bacteria may cause type 2 diabetes

June 1, 2015

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.